3 completed. 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Wandering Behavior: new trials by email Literature Review of Wandering Behavior trials Research Report on Wandering Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fasudil fOr redUcing elopemeNt and Spatial Disorientation Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day, Oral Placebo - Dementia | Phase 2 | Completed | Woolsey Pharmaceuticals | 24 | 2020-12-15 | 2022-07-11 |
| A Pilot Study to Characterize the Household Impact of Locating Devices for Children With ASD Who Wander Electronic Tracking Device - Autism Spectrum Disorder, Wandering Behavior | Not applicable | Completed | Northwell Health | 31 | 2019-01-15 | 2021-01-05 |
| Securing the Immediate Perioperative Walk: Creating and Validating a Score. Perioperative score - Wandering Behavior, Anesthesia | Not applicable | Completed | GCS Ramsay Santé pour l'Enseignement et la Recherche | 525 | 2018-04-23 | 2026-07-16 |
Autism Spectrum Disorder (1) · Dementia (1)
Aberrant Motor Behavior in Dementia (3) · Behavior (3) · Behavioral Symptoms (3) · Mental Disorders (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Child Development Disorders, Pervasive (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodevelopmental Disorders (1)
fasudil (1)
GCS Ramsay Santé pour l'Enseignement et la Recherche (1) · Northwell Health (1) · Woolsey Pharmaceuticals (1)
United States (2) · Australia (1) · France (1)